{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-002956","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2022-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.074976+00:00","generated_at":"2026-06-27T01:04:49.059619+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"KalVista initiates Phase 3 KONFIDENT trial of KVD900 for HAE attacks","bullets":["KVD900 is first potential oral on-demand therapy for HAE; all current on-demand therapies are injectable.","Trial is double-blind, placebo-controlled, crossover; two doses (300 mg, 600 mg) vs placebo.","Primary endpoint: time to beginning of symptom relief per Patient Global Impression of Change (PGI-C) scale.","Enrollment: minimum 84 adolescent and adult patients at ~60 sites in 20 countries.","Top-line data expected in second half of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-002956","json":"https://secwatch.observer/filing/0000950170-22-002956.json","markdown":"https://secwatch.observer/filing/0000950170-22-002956.md","text":"https://secwatch.observer/filing/0000950170-22-002956.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017022002956/0000950170-22-002956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017022002956/kalv-20220307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T01:04:49.059619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}